Lysogene Announces Company Presentations at October & November Investor Conferences

Regulatory News:

Lysogene (Paris:LYS) (FR0013233475 – LYS) (LYS.PA), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it will be participating in the following investor events in the upcoming weeks:

October

• Chardan Gene Therapy Conference (New York, US)

• Jefferies Gene Editing & Gene Therapy Summit (New York, US)

• Key Opinion Leader Lunch: Gene Therapy for Patients with Sanfilippo Syndrome Type A (MPS IIIA) (New York, US)

Webcast: http://lifesci.rampard.com/20171013/reg.jsp

November

• Jefferies 2017 London Healthcare Conference (London, UK)

About Lysogene

Lysogene (www.lysogene.com) is a global biopharma leader in orphan CNS disease research and development. Lysogene has generated five non-cumulative years of clinical safety data to show the efficiency of a direct delivery route to the CNS with its initial gene therapy trial for MPS IIIA. Lysogene has recently completed the enrollment for the first multi-national observational study in MPS IIIA which will function as the non-concurrent control for the first pivotal trial for MPS IIIA in H1 2018. Lysogene also plans a clinical trial for GM1 Gangliosidosis for 2019. Lysogene has obtained orphan drug designation from the EMA and FDA and rare pediatric designation by the FDA for both programs.

Lysogene is listed on the Euronext regulated market in Paris (ISIN code: FR0013233475).

For more information: www.lysogene.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171004006009/en/